title: Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen.
authors.forename: Franck
authors.initials: F
authors.lastname: Bürki
authors.forename: Kattalin
authors.initials: K
authors.lastname: Badie
authors.forename: Philippe
authors.initials: P
authors.lastname: Bartoli
authors.forename: Pascale
authors.initials: P
authors.lastname: Bernard
authors.forename: Jean Louis
authors.initials: JL
authors.lastname: Montastruc
authors.forename: Haleh
authors.initials: H
authors.lastname: Bagheri
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004317:Doxorubicin